DCM
SGMO

Delpha Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Delpha Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-273
Closed -$4K – 1027
2017
Q4 		$4K Buy
+273
New +$4.06K ﹤0.01% 1364

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Delpha Capital Management's SGMO Position: Q1 2018 in Review

Delpha Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2018, closing a stake of 273 shares — an estimated $4K sold.

Delpha Capital Management first reported a position in SGMO in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 208 funds tracked by Wall St. Rank hold SGMO as of Q1 2018.

  • Delpha Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 273 SANGAMO THERAPEUTICS INC shares in Q1 2018, an estimated $4K.
  • Delpha Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's SANGAMO THERAPEUTICS INC position peaked at $4K in Q4 2017.
  • 208 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.